A glucometer for cancer: towards a scalable, universal residual disease measurement By Ogkologos - October 23, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... July 4, 2025 Stopping neuropathy: One of chemotherapy’s most challenging side effects May 22, 2023 Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... August 26, 2024 Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom... May 29, 2019 Load more HOT NEWS Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... New on NCI’s Websites for March 2021
